Business
Statement re price movement and press speculation
Statement re price movement and press speculation.
About this update from Hvivo Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 9872Z\n Open Orphan PLC\n 24 September 2020\n \n \n \n \n 24 September 2020\n \n \n Open Orphan plc\n \n \n (\"Open Orphan\" or the \"Company\")\n \n \n Statement re price movement and press speculation\n \n \n Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials notes the recent share price movement and press speculation regarding UK government-funded Coronavirus human challenge studies.\n \n \n The Company confirms that it is in advanced negotiation with the UK Government and other partners for a Coronavirus challenge study in the UK. While negotiations continue, it is expected that in the event that a contract is agreed revenue will be in excess of £7 million, being the approximate anticipated revenue for a Coronavirus challenge study as indicated by the Company on 22 May 2020. However, there can be no certainty that these discussions will lead to a new contract until final negotiations are concluded. The Company will update the market in due course as appropriate.\n \n \n Further to its announcements of 9 March 2020 and 22 May 2020 regarding the development by the Company of a Coronavirus challenge study model the Company remains in ongoing discussions with potential vaccine developers regarding Coronavirus challenge studies.\n \n \n The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 (\"MAR\"). With the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.\n \n \n ENDS\n \n \n \n \n \n For further information please contact\n \n \n \n \n \n Open Orphan plc\n \n \n \n \n +353 (0)1 644 0007\n \n \n \n \n \n \n Cathal Friel, Executive Chairman\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Arden Partners plc (Nominated Adviser and Joint Broker)\n \n \n \n \n +44 (0)20 7614 5900\n \n \n \n \n \n \n John Llewellyn-Lloyd / Benjamin Cryer / Dan Gee-Summons\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n finnCap plc (Joint Broker)\n \n \n \n \n +44 (0) 20 7220 500\n \...